

Todd M Morgan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2940833/publications.pdf>

Version: 2024-02-01

229
papers

8,445
citations

41344

49
h-index

64796

79
g-index

234
all docs

234
docs citations

234
times ranked

10917
citing authors

#	ARTICLE	IF	CITATIONS
1	Association of Black Race With Prostate Cancerâ€™Specific and Other-Cause Mortality. <i>JAMA Oncology</i> , 2019, 5, 975.	7.1	288
2	NCCN Guidelines Insights: Prostate Cancer Early Detection, Version 2.2016. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 509-519.	4.9	268
3	Stereotactic Body Radiation Therapy for Localized Prostate Cancer: A Systematic Review and Meta-Analysis of Over 6,000 Patients Treated On Prospective Studies. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 778-789.	0.8	247
4	Targeted Therapy for Advanced Prostate Cancer: Inhibition of the PI3K/Akt/mTOR Pathway. <i>Current Cancer Drug Targets</i> , 2009, 9, 237-249.	1.6	244
5	Considerations in the Triage of Urologic Surgeries During the COVID-19 Pandemic. <i>European Urology</i> , 2020, 77, 663-666.	1.9	239
6	Multicenter Assessment of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer. <i>European Urology</i> , 2015, 67, 241-249.	1.9	235
7	Disseminated Tumor Cells in Prostate Cancer Patients after Radical Prostatectomy and without Evidence of Disease Predicts Biochemical Recurrence. <i>Clinical Cancer Research</i> , 2009, 15, 677-683.	7.0	218
8	Hairpin-bisulfite PCR: Assessing epigenetic methylation patterns on complementary strands of individual DNA molecules. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 204-209.	7.1	203
9	The DNA methylation landscape of advanced prostate cancer. <i>Nature Genetics</i> , 2020, 52, 778-789.	21.4	198
10	Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019. <i>Journal of Clinical Oncology</i> , 2020, 38, 2798-2811.	1.6	170
11	Preoperative Nutritional Status Is an Important Predictor of Survival in Patients Undergoing Surgery for Renal Cell Carcinoma. <i>European Urology</i> , 2011, 59, 923-928.	1.9	146
12	Molecular Biomarkers in Localized Prostate Cancer: ASCO Guideline. <i>Journal of Clinical Oncology</i> , 2020, 38, 1474-1494.	1.6	141
13	HER2 and EGFR Overexpression Support Metastatic Progression of Prostate Cancer to Bone. <i>Cancer Research</i> , 2017, 77, 74-85.	0.9	137
14	Single-cell analyses of renal cell cancers reveal insights into tumor microenvironment, cell of origin, and therapy response. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	136
15	Clinically Localized Prostate Cancer: ASCO Clinical Practice Guideline Endorsement of an American Urological Association/American Society for Radiation Oncology/Society of Urologic Oncology Guideline. <i>Journal of Clinical Oncology</i> , 2018, 36, 3251-3258.	1.6	129
16	Cabozantinib Eradicates Advanced Murine Prostate Cancer by Activating Antitumor Innate Immunity. <i>Cancer Discovery</i> , 2017, 7, 750-765.	9.4	112
17	Risks from Deferring Treatment for Genitourinary Cancers: A Collaborative Review to Aid Triage and Management During the COVID-19 Pandemic. <i>European Urology</i> , 2020, 78, 29-42.	1.9	110
18	Apoptosis-induced CXCL5 accelerates inflammation and growth of prostate tumor metastases in bone. <i>Journal of Clinical Investigation</i> , 2017, 128, 248-266.	8.2	103

#	ARTICLE	IF	CITATIONS
19	Predicting the Probability of 90-Day Survival of Elderly Patients With Bladder Cancer Treated With Radical Cystectomy. <i>Journal of Urology</i> , 2011, 186, 829-834.	0.4	97
20	Genomic Profiling of Penile Squamous Cell Carcinoma Reveals New Opportunities for Targeted Therapy. <i>Cancer Research</i> , 2015, 75, 5219-5227.	0.9	94
21	A Systematic Review of the Evidence for the Decipher Genomic Classifier in Prostate Cancer. <i>European Urology</i> , 2021, 79, 374-383.	1.9	93
22	Prognostic Value of Percent Gleason Grade 4 at Prostate Biopsy in Predicting Prostatectomy Pathology and Recurrence. <i>Journal of Urology</i> , 2016, 196, 405-411.	0.4	89
23	The relationship between perioperative blood transfusion and overall mortality in patients undergoing radical cystectomy for bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 871-877.	1.6	86
24	Development of an Automated and Sensitive Microfluidic Device for Capturing and Characterizing Circulating Tumor Cells (CTCs) from Clinical Blood Samples. <i>PLoS ONE</i> , 2016, 11, e0147400.	2.5	82
25	Intermediate clinical endpoints for surrogacy in localised prostate cancer: an aggregate meta-analysis. <i>Lancet Oncology</i> , The, 2021, 22, 402-410.	10.7	79
26	NRG Oncology Updated International Consensus Atlas on Pelvic Lymph Node Volumes for Intact and Postoperative Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 174-185.	0.8	77
27	Prostate Cancer Early Detection, Version 1.2014. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 1211-1219.	4.9	76
28	Very Early Salvage Radiotherapy Improves Distant Metastasis-Free Survival. <i>Journal of Urology</i> , 2017, 197, 662-668.	0.4	76
29	Gleason 6 Prostate Cancer: Translating Biology into Population Health. <i>Journal of Urology</i> , 2015, 194, 626-634.	0.4	75
30	Engaging responsibly with social media: the <sc>BJU</sc> guidelines. <i>BJU International</i> , 2014, 114, 9-11.	2.5	74
31	Telemedicine in Urology: State of the Art. <i>Urology</i> , 2016, 94, 10-16.	1.0	74
32	Transcriptomic Heterogeneity of Androgen Receptor Activity Defines a <i>de novo</i> low AR-Active Subclass in Treatment Naïve Primary Prostate Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 6721-6730.	7.0	74
33	European Association of Urology (@Uroweb) Recommendations on the Appropriate Use of Social Media. <i>European Urology</i> , 2014, 66, 628-632.	1.9	72
34	Transcriptomic heterogeneity in multifocal prostate cancer. <i>JCI Insight</i> , 2018, 3, .	5.0	71
35	Incidence and predictors of understaging in patients with clinical <sc>T</sc>1 urothelial carcinoma undergoing radical cystectomy. <i>BJU International</i> , 2014, 113, 894-899.	2.5	67
36	Sharpening the focus on causes and timing of readmission after radical cystectomy for bladder cancer. <i>Cancer</i> , 2014, 120, 1409-1416.	4.1	65

#	ARTICLE	IF	CITATIONS
37	RAD001 (Everolimus) inhibits growth of prostate cancer in the bone and the inhibitory effects are increased by combination with docetaxel and zoledronic acid. <i>Prostate</i> , 2008, 68, 861-871.	2.3	64
38	A Multigene Signature Based on Cell Cycle Proliferation Improves Prediction of Mortality Within 5 Yr of Radical Nephrectomy for Renal Cell Carcinoma. <i>European Urology</i> , 2018, 73, 763-769.	1.9	63
39	Evaluating the Four Kallikrein Panel of the 4Kscore for Prediction of High-grade Prostate Cancer in Men in the Canary Prostate Active Surveillance Study. <i>European Urology</i> , 2017, 72, 448-454.	1.9	61
40	Reasons for Discontinuing Active Surveillance: Assessment of 21 Centres in 12 Countries in the Movember GAP3 Consortium. <i>European Urology</i> , 2019, 75, 523-531.	1.9	58
41	Association of Presalvage Radiotherapy PSA Levels After Prostatectomy With Outcomes of Long-term Antiandrogen Therapy in Men With Prostate Cancer. <i>JAMA Oncology</i> , 2020, 6, 735.	7.1	58
42	Complications of Scrotal Surgery for Benign Conditions. <i>Urology</i> , 2007, 69, 616-619.	1.0	57
43	Volume Outcomes of Cystectomy—Is it the Surgeon or the Setting?. <i>Journal of Urology</i> , 2012, 188, 2139-2144.	0.4	57
44	A Systematic Review and Framework for the Use of Hormone Therapy with Salvage Radiation Therapy for Recurrent Prostate Cancer. <i>European Urology</i> , 2018, 73, 156-165.	1.9	55
45	Performance of a Prostate Cancer Genomic Classifier in Predicting Metastasis in Men with Prostate-specific Antigen Persistence Postprostatectomy. <i>European Urology</i> , 2018, 74, 107-114.	1.9	54
46	Staging the Host: Personalizing Risk Assessment for Radical Cystectomy Patients. <i>European Urology Oncology</i> , 2018, 1, 292-304.	5.4	54
47	Targeted DNA and RNA Sequencing of Paired Urothelial and Squamous Bladder Cancers Reveals Discordant Genomic and Transcriptomic Events and Unique Therapeutic Implications. <i>European Urology</i> , 2018, 74, 741-753.	1.9	54
48	Prostate Radiotherapy With Adjuvant Androgen Deprivation Therapy (ADT) Improves Metastasis-Free Survival Compared to Neoadjuvant ADT: An Individual Patient Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2021, 39, 136-144.	1.6	52
49	Prognostic factors and outcomes in primary urethral cancer: results from the international collaboration on primary urethral carcinoma. <i>World Journal of Urology</i> , 2016, 34, 97-103.	2.2	51
50	Primary Scrotal Cancer: Disease Characteristics and Increasing Incidence. <i>Urology</i> , 2008, 72, 1139-1143.	1.0	50
51	Genomic Alterations Indicate Tumor Origin and Varied Metastatic Potential of Disseminated Cells from Prostate Cancer Patients. <i>Cancer Research</i> , 2008, 68, 5599-5608.	0.9	50
52	Development and Validation of a Clinical Prognostic Stage Group System for Nonmetastatic Prostate Cancer Using Disease-Specific Mortality Results From the International Staging Collaboration for Cancer of the Prostate. <i>JAMA Oncology</i> , 2020, 6, 1912.	7.1	49
53	Independent surgical validation of the new prostate cancer grade—grouping system. <i>BJU International</i> , 2016, 118, 763-769.	2.5	48
54	17-Gene Genomic Prostate Score Test Results in the Canary Prostate Active Surveillance Study (PASS) Cohort. <i>Journal of Clinical Oncology</i> , 2020, 38, 1549-1557.	1.6	48

#	ARTICLE	IF	CITATIONS
55	ABO blood group is a predictor of survival in patients undergoing surgery for renal cell carcinoma. <i>BJU International</i> , 2012, 110, E641-6.	2.5	47
56	CXCL12 ⁺ Promotes Metastatic Castration-Resistant Prostate Cancer by Inducing Cancer Stem Cell and Neuroendocrine Phenotypes. <i>Cancer Research</i> , 2018, 78, 2026-2039.	0.9	46
57	Rapid, ultra low coverage copy number profiling of cell-free DNA as a precision oncology screening strategy. <i>Oncotarget</i> , 2017, 8, 89848-89866.	1.8	45
58	Lymph Node Yield at Radical Cystectomy Predicts Mortality in Node-negative and not Node-positive Patients. <i>Urology</i> , 2012, 80, 632-640.	1.0	44
59	Anatomic Basis for Lymph Node Counts as Measure of Lymph Node Dissection Extent: A Cadaveric Study. <i>Urology</i> , 2013, 81, 358-363.	1.0	43
60	Molecular and Immunohistochemical Characterization Reveals Novel BRAF Mutations in Metanephric Adenoma. <i>American Journal of Surgical Pathology</i> , 2015, 39, 549-557.	3.7	43
61	Bladder cancer. <i>Current Opinion in Oncology</i> , 2011, 23, 275-282.	2.4	40
62	Imaging the Clear Cell Renal Cell Carcinoma Proteome. <i>Journal of Urology</i> , 2013, 189, 1097-1103.	0.4	40
63	Treatment of Nonmetastatic Muscle-Invasive Bladder Cancer: American Urological Association/American Society of Clinical Oncology/American Society for Radiation Oncology/Society of Urologic Oncology Clinical Practice Guideline Summary. <i>Journal of Oncology Practice</i> , 2017, 13, 621-625.	2.5	40
64	HRAS mutations are frequent in inverted urothelial neoplasms. <i>Human Pathology</i> , 2014, 45, 1957-1965.	2.0	39
65	The Impact of the COVID-19 Pandemic on Genitourinary Cancer Care: Re-envisioning the Future. <i>European Urology</i> , 2020, 78, 731-742.	1.9	39
66	Epidemiology of the Small Renal Mass and the Treatment Disconnect Phenomenon. <i>Urologic Clinics of North America</i> , 2017, 44, 147-154.	1.8	37
67	Understanding Treatment Disconnect and Mortality Trends in Renal Cell Carcinoma Using Tumor Registry Data. <i>Medical Care</i> , 2017, 55, 398-404.	2.4	36
68	Wnt Signaling Drives Prostate Cancer Bone Metastatic Tropism and Invasion. <i>Translational Oncology</i> , 2020, 13, 100747.	3.7	36
69	Recent Advances in Epigenetic Biomarkers and Epigenetic Targeting in Prostate Cancer. <i>European Urology</i> , 2021, 80, 71-81.	1.9	35
70	Prostate cancer therapy personalization via multi-modal deep learning on randomized phase III clinical trials. <i>Npj Digital Medicine</i> , 2022, 5, .	10.9	34
71	Multigene Profiling of CTCs in mCRPC Identifies a Clinically Relevant Prognostic Signature. <i>Molecular Cancer Research</i> , 2018, 16, 643-654.	3.4	33
72	Bladder cancer. <i>Current Opinion in Oncology</i> , 2010, 22, 242-249.	2.4	32

#	ARTICLE	IF	CITATIONS
73	Circulating Tumor Cellâ€Based Molecular Classifier for Predicting Resistance to Abiraterone and Enzalutamide in Metastatic Castration-Resistant Prostate Cancer. <i>Neoplasia</i> , 2019, 21, 802-809.	5.3	32
74	Development and Validation of a Deep-learning Model to Assist With Renal Cell Carcinoma Histopathologic Interpretation. <i>Urology</i> , 2020, 144, 152-157.	1.0	32
75	The Use of Social Media in Endourology: An Analysis of the 2013 World Congress of Endourology Meeting. <i>Journal of Endourology</i> , 2015, 29, 615-620.	2.1	31
76	Refined Analysis of Prostate-specific Antigen Kinetics to Predict Prostate Cancer Active Surveillance Outcomes. <i>European Urology</i> , 2018, 74, 211-217.	1.9	30
77	Detection of CTC Clusters and a Dedifferentiated RNAâ€Expression Survival Signature in Prostate Cancer. <i>Advanced Science</i> , 2019, 6, 1801254.	11.2	30
78	Tailoring Intensity of Active Surveillance for Low-Risk Prostate Cancer Based on Individualized Prediction of Risk Stability. <i>JAMA Oncology</i> , 2020, 6, e203187.	7.1	30
79	African American Race is Not Associated with Risk of Reclassification during Active Surveillance: Results from the Canary Prostate Cancer Active Surveillance Study. <i>Journal of Urology</i> , 2020, 203, 727-733.	0.4	30
80	Endogenous GAS6 and Mer receptor signaling regulate prostate cancer stem cells in bone marrow. <i>Oncotarget</i> , 2016, 7, 25698-25711.	1.8	30
81	Hypoalbuminaemia is associated with mortality in patients undergoing cytoreductive nephrectomy. <i>BJU International</i> , 2015, 116, 351-357.	2.5	29
82	Intermediate Endpoints After Postprostatectomy Radiotherapy: 5-Year Distant Metastasis to Predict Overall Survival. <i>European Urology</i> , 2018, 74, 413-419.	1.9	29
83	The prognostic value of the neutrophil-to-lymphocyte ratio in patients with muscle-invasive bladder cancer treated with neoadjuvant chemotherapy and radical cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 3.e17-3.e27.	1.6	29
84	Assessment of longâ€term outcomes associated with urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion at repeat biopsy. <i>Cancer</i> , 2015, 121, 4071-4079.	4.1	28
85	The State of the Science on Prostate Cancer Biomarkers: The San Francisco Consensus Statement. <i>European Urology</i> , 2019, 76, 268-272.	1.9	28
86	Impact of a Genomic Classifier of Metastatic Risk on Postprostatectomy Treatment Recommendations by Radiation Oncologists and Urologists. <i>Urology</i> , 2015, 86, 35-40.	1.0	27
87	No Differences in Population-based Readmissions After Open and Robotic-assisted Radical Cystectomy: Implications for Post-discharge Care. <i>Urology</i> , 2017, 104, 77-83.	1.0	27
88	Minimally Invasive Inguinal Lymphadenectomy in the Management of Penile Carcinoma. <i>Urology</i> , 2017, 106, 113-118.	1.0	26
89	Examining the Value of Video Visits to Patients in an Outpatient Urology Clinic. <i>Urology</i> , 2017, 110, 31-35.	1.0	26
90	Multi-institutional Survival Analysis of Incidental Pathologic T3a Upstaging in Clinical T1 Renal Cell Carcinoma Following Partial Nephrectomy. <i>Urology</i> , 2018, 117, 95-100.	1.0	26

#	ARTICLE	IF	CITATIONS
91	Addition of Androgen-Deprivation Therapy or Brachytherapy Boost to External Beam Radiotherapy for Localized Prostate Cancer: A Network Meta-Analysis of Randomized Trials. <i>Journal of Clinical Oncology</i> , 2020, 38, 3024-3031.	1.6	26
92	Thymic stromal organization is regulated by the specificity of T cell receptor/major histocompatibility complex interactions. <i>European Journal of Immunology</i> , 1997, 27, 136-146.	2.9	25
93	Papillary renal cell carcinoma revisited: a comprehensive histomorphologic study with outcome correlations. <i>Human Pathology</i> , 2014, 45, 1139-1146.	2.0	25
94	Transperineal Template Guided Prostate Biopsy Selects Candidates for Active Surveillance—How Many Cores are Enough?. <i>Journal of Urology</i> , 2015, 194, 674-679.	0.4	25
95	Statin use is associated with improved survival in patients undergoing surgery for renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 21.e11-21.e17.	1.6	25
96	Mechanistic Support for Combined MET and AR Blockade in Castration-Resistant Prostate Cancer. <i>Neoplasia</i> , 2016, 18, 1-9.	5.3	25
97	Programmed Death-ligand 1 Expression in Upper Tract Urothelial Carcinoma. <i>European Urology Focus</i> , 2017, 3, 502-509.	3.1	25
98	Molecular Profiling to Determine Clonality of Serial Magnetic Resonance Imaging/Ultrasound Fusion Biopsies from Men on Active Surveillance for Low-Risk Prostate Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 985-991.	7.0	24
99	Erectile function after stereotactic body radiotherapy for localized prostate cancer. <i>BJU International</i> , 2018, 121, 61-68.	2.5	24
100	Adherence to Active Surveillance Protocols for Low-risk Prostate Cancer: Results of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance Initiative. <i>European Urology Oncology</i> , 2020, 3, 80-91.	5.4	24
101	Growth Arrest-Specific 6 (GAS6) Promotes Prostate Cancer Survival by G ₁ Arrest/S Phase Delay and Inhibition of Apoptosis During Chemotherapy in Bone Marrow. <i>Journal of Cellular Biochemistry</i> , 2016, 117, 2815-2824.	2.6	23
102	Individual Patient Data Analysis of Randomized Clinical Trials: Impact of Black Race on Castration-resistant Prostate Cancer Outcomes. <i>European Urology Focus</i> , 2016, 2, 532-539.	3.1	23
103	The Feasibility and Impact of a Presurgical Exercise Intervention Program (Prehabilitation) for Patients Undergoing Cystectomy for Bladder Cancer. <i>Urology</i> , 2020, 145, 106-112.	1.0	23
104	Biomarkers for detection of clinically significant prostate cancer: contemporary clinical data and future directions. <i>Translational Andrology and Urology</i> , 2021, 10, 3091-3103.	1.4	23
105	Predictors of Delayed Intervention for Patients on Active Surveillance for Small Renal Masses: Does Renal Mass Biopsy Influence Our Decision?. <i>Urology</i> , 2016, 98, 88-96.	1.0	22
106	Performance of PCA3 and TMPRSS2:ERG urinary biomarkers in prediction of biopsy outcome in the Canary Prostate Active Surveillance Study (PASS). <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 438-445.	3.9	22
107	Current and Emerging Therapies for Metastatic Castration-Resistant Prostate Cancer (mCRPC). <i>Biomedicines</i> , 2021, 9, 1247.	3.2	22
108	Urinary Collecting System Invasion Is a Predictor for Overall and Disease-specific Survival in Locally Invasive Renal Cell Carcinoma. <i>Urology</i> , 2011, 78, 99-104.	1.0	21

#	ARTICLE	IF	CITATIONS
109	Pathological upgrading at radical prostatectomy for patients with Grade Group 1 prostate cancer: implications of confirmatory testing for patients considering active surveillance. <i>BJU International</i> , 2019, 123, 846-853.	2.5	21
110	Correlation between cribriform/intraductal prostatic adenocarcinoma and percent Gleason pattern 4 to a 22-gene genomic classifier. <i>Prostate</i> , 2020, 80, 146-152.	2.3	21
111	Use of the MyProstateScore Test to Rule Out Clinically Significant Cancer: Validation of a Straightforward Clinical Testing Approach. <i>Journal of Urology</i> , 2021, 205, 732-739.	0.4	21
112	A Clinical Decision Aid to Support Personalized Treatment Selection for Patients with Clinical T1 Renal Masses: Results from a Multi-institutional Competing-risks Analysis. <i>European Urology</i> , 2022, 81, 576-585.	1.9	21
113	Utilization of Salvage Radiation Therapy for Biochemical Recurrence After Radical Prostatectomy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 1030-1034.	0.8	20
114	Surgical and Chemotherapeutic Management of Regional Lymph Nodes in Bladder Cancer. <i>Journal of Urology</i> , 2012, 188, 1081-1088.	0.4	19
115	Magnetic Resonance Imaging for the Detection of High Grade Cancer in the Canary Prostate Active Surveillance Study. <i>Journal of Urology</i> , 2020, 204, 701-706.	0.4	19
116	Oncologic outcomes in patients with nonurothelial bladder cancer. <i>Indian Journal of Urology</i> , 2018, 34, 39.	0.6	19
117	Standardizing the definition of adverse pathology for lower risk men undergoing radical prostatectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 415.e1-415.e6.	1.6	18
118	Detection and isolation of disseminated tumor cells in bone marrow of patients with clinically localized prostate cancer. <i>Prostate</i> , 2019, 79, 1715-1727.	2.3	18
119	Predicting Biopsy Outcomes During Active Surveillance for Prostate Cancer: External Validation of the Canary Prostate Active Surveillance Study Risk Calculators in Five Large Active Surveillance Cohorts. <i>European Urology</i> , 2019, 76, 693-702.	1.9	18
120	Circulating Tumor Cells as a Predictor of Treatment Response in Clinically Localized Prostate Cancer. <i>JCO Precision Oncology</i> , 2019, 3, 1-9.	3.0	18
121	De novo neuroendocrine transdifferentiation in primary prostate cancer—a phenotype associated with advanced clinico-pathologic features and aggressive outcome. <i>Medical Oncology</i> , 2021, 38, 26.	2.5	18
122	International Multicenter Validation of an Intermediate Risk Subclassification of Prostate Cancer Managed with Radical Treatment without Hormone Therapy. <i>Journal of Urology</i> , 2019, 201, 284-291.	0.4	18
123	Role of Surveillance Biopsy with No Cancer as a Prognostic Marker for Reclassification: Results from the Canary Prostate Active Surveillance Study. <i>European Urology</i> , 2018, 73, 706-712.	1.9	17
124	Individual and Population Comparisons of Surgery and Radiotherapy Outcomes in Prostate Cancer Using Bayesian Multistate Models. <i>JAMA Network Open</i> , 2019, 2, e187765.	5.9	17
125	Performance of clinicopathologic models in men with high risk localized prostate cancer: impact of a 22-gene genomic classifier. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 646-653.	3.9	17
126	Blood loss associated with radical cystectomy: A prospective, randomized study comparing Impact LigaSure vs. stapling device. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 45.e11-45.e15.	1.6	16

#	ARTICLE	IF	CITATIONS
127	Comparison of Percutaneous Renal Mass Biopsy and R.E.N.A.L. Nephrometry Score Nomograms for Determining Benign Vs Malignant Disease and Low-risk Vs High-risk Renal Tumors. <i>Urology</i> , 2016, 96, 87-92.	1.0	16
128	Clinical utility and concordance of upper urinary tract cytology and biopsy in predicting clinicopathological features of upper urinary tract urothelial carcinoma. <i>Human Pathology</i> , 2019, 86, 76-84.	2.0	16
129	Clinical implications of genomic evaluations for prostate cancer risk stratification, screening, and treatment: a narrative review. <i>Prostate International</i> , 2020, 8, 99-106.	2.3	16
130	Comparison of Response to Definitive Radiotherapy for Localized Prostate Cancer in Black and White Men. <i>JAMA Network Open</i> , 2021, 4, e2139769.	5.9	16
131	Patient Psoas Muscle Mass as a Predictor of Complications and Survival After Radical Cystectomy. <i>Current Urology Reports</i> , 2015, 16, 79.	2.2	15
132	The Role of Transurethral Resection in Trimodal Therapy for Muscle-Invasive Bladder Cancer. <i>Bladder Cancer</i> , 2016, 2, 381-394.	0.4	15
133	Age, Gender and R.E.N.A.L. Nephrometry Score do not Improve the Accuracy of a Risk Stratification Algorithm Based on Biopsy and Mass Size for Assigning Surveillance versus Treatment of Renal Tumors. <i>Journal of Urology</i> , 2016, 195, 574-580.	0.4	15
134	Adjuvant Versus Early Salvage Radiation Therapy Following Radical Prostatectomy for Men with Localized Prostate Cancer. <i>Current Urology Reports</i> , 2017, 18, 55.	2.2	15
135	Clinical and morphologic review of 60 hereditary renal tumors from 30 hereditary renal cell carcinoma syndrome patients: lessons from a contemporary single institution series. <i>Medical Oncology</i> , 2019, 36, 74.	2.5	15
136	Adrenergic Blockade Promotes Maintenance of Dormancy in Prostate Cancer Through Upregulation of GAS6. <i>Translational Oncology</i> , 2020, 13, 100781.	3.7	15
137	Impact of sex on response to neoadjuvant chemotherapy in patients with bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 639.e1-639.e9.	1.6	15
138	Personalised biopsy schedules based on risk of Gleason upgrading for patients with low-risk prostate cancer on active surveillance. <i>BJU International</i> , 2021, 127, 96-107.	2.5	15
139	Impact of Decipher Biopsy testing on clinical outcomes in localized prostate cancer in a prospective statewide collaborative. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 677-683.	3.9	15
140	Understanding the Relationship Between Tumor Size, Gland Size, and Disease Aggressiveness in Men With Prostate Cancer. <i>Urology</i> , 2014, 84, 373-379.	1.0	14
141	Potential Implications of Shortening Length of Stay Following Radical Cystectomy in a Pre-ERAS Population. <i>Urology</i> , 2017, 102, 92-99.	1.0	14
142	Factors Associated with Time to Conversion from Active Surveillance to Treatment for Prostate Cancer in a Multi-Institutional Cohort. <i>Journal of Urology</i> , 2021, 206, 1147-1156.	0.4	14
143	A Multi-Center International Study Assessing the Impact of Differences in Baseline Characteristics and Perioperative Care Following Radical Cystectomy. <i>Bladder Cancer</i> , 2016, 2, 251-261.	0.4	13
144	Prognostic importance of lymphovascular invasion in urothelial carcinoma of the renal pelvis. <i>Cancer</i> , 2018, 124, 2507-2514.	4.1	13

#	ARTICLE	IF	CITATIONS
145	The Fate of Radical Cystectomy Patients after Hospital Discharge: Understanding the Black Box of the Pre-admission Interval. <i>European Urology Focus</i> , 2018, 4, 711-717.	3.1	13
146	Clinical Utility of Gene Expression Classifiers in Men With Newly Diagnosed Prostate Cancer. <i>JCO Precision Oncology</i> , 2018, 2, 1-15.	3.0	13
147	Active surveillance for prostate cancer: selection criteria, guidelines, and outcomes. <i>World Journal of Urology</i> , 2022, 40, 35-42.	2.2	13
148	Prostate Cancer Patients Under Active Surveillance with a Suspicious Magnetic Resonance Imaging Finding Are at Increased Risk of Needing Treatment: Results of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium. <i>European Urology Open Science</i> , 2022, 35, 59-67.	0.4	13
149	Impact of tertiary Gleason pattern 5 on prostate cancer aggressiveness: Lessons from a contemporary single institution radical prostatectomy series. <i>Asian Journal of Urology</i> , 2015, 2, 53-58.	1.2	12
150	Effect of delayed resection after initial surveillance and tumor growth rate on final surgical pathology in patients with small renal masses (SRMs). <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 486.e9-486.e15.	1.6	12
151	Two-Stage Biomarker Protocols for Improving the Precision of Early Detection of Prostate Cancer. <i>Medical Decision Making</i> , 2017, 37, 815-826.	2.4	12
152	The prognostic effect of salvage surgery and radiotherapy in patients with recurrent primary urethral carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 10.e7-10.e14.	1.6	12
153	Multigene model for predicting metastatic prostate cancer using circulating tumor cells by microfluidic magnetophoresis. <i>Cancer Science</i> , 2021, 112, 859-870.	3.9	11
154	Antisense oligonucleotides and nucleic acids generate hypersensitive platelets. <i>Thrombosis Research</i> , 2021, 200, 64-71.	1.7	11
155	The European Urology Commitment to Gender Equity and Diversity: Expanding Cognitive Diversity through Inclusivity at the Podium. <i>European Urology</i> , 2021, 80, 450-453.	1.9	11
156	Clinicopathologic characteristics of anterior prostate cancer (APC), including correlation with previous biopsy pathology. <i>Medical Oncology</i> , 2015, 32, 249.	2.5	10
157	Anatomical patterns of recurrence following biochemical relapse after post-prostatectomy salvage radiation therapy: a multi-institutional study. <i>BJU International</i> , 2017, 120, 351-357.	2.5	10
158	Association Between Early Confirmatory Testing and the Adoption of Active Surveillance for Men With Favorable-risk Prostate Cancer. <i>Urology</i> , 2018, 118, 127-133.	1.0	10
159	Overdiagnosis and Lives Saved by Reflex Testing Men With Intermediate Prostate-Specific Antigen Levels. <i>Journal of the National Cancer Institute</i> , 2020, 112, 384-390.	6.3	10
160	Neoadjuvant chemotherapy plus radical cystectomy versus radical cystectomy alone in clinical T2 bladder cancer without hydronephrosis. <i>BJU International</i> , 2021, 128, 79-87.	2.5	10
161	Biopsy Cell Cycle Proliferation Score Predicts Adverse Surgical Pathology in Localized Renal Cell Carcinoma. <i>European Urology</i> , 2020, 78, 657-660.	1.9	10
162	Comparative effectiveness of neoadjuvant chemotherapy in bladder and upper urinary tract urothelial carcinoma. <i>BJU International</i> , 2021, 127, 528-537.	2.5	10

#	ARTICLE	IF	CITATIONS
163	Genetic factors associated with prostate cancer conversion from active surveillance to treatment. <i>Human Genetics and Genomics Advances</i> , 2022, 3, 100070.	1.7	10
164	Estimating the Optimal Personalized Treatment Strategy Based on Selected Variables to Prolong Survival via Random Survival Forest with Weighted Bootstrap. <i>Journal of Biopharmaceutical Statistics</i> , 2018, 28, 362-381.	0.8	9
165	Clinical outcomes in men with prostate cancer who selected active surveillance using a clinical cell cycle risk score. <i>Personalized Medicine</i> , 2019, 16, 491-499.	1.5	9
166	Liquid biopsy: Where did it come from, what is it, and where is it going?. <i>Investigative and Clinical Urology</i> , 2019, 60, 139.	2.0	9
167	Biologic Significance of Magnetic Resonance Imaging Invisibility in Localized Prostate Cancer. <i>JCO Precision Oncology</i> , 2019, 3, 1-12.	3.0	9
168	Economic Evaluation of Urine-Based or Magnetic Resonance Imaging Reflex Tests in Men With Intermediate Prostate-Specific Antigen Levels in the United States. <i>Value in Health</i> , 2021, 24, 1111-1117.	0.3	9
169	Platelet-Synthesized Testosterone in Men with Prostate Cancer Induces Androgen Receptor Signaling. <i>Neoplasia</i> , 2015, 17, 490-496.	5.3	8
170	Treatment of ureteral anastomotic strictures with reimplantation and survival after cystectomy and urinary diversion. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 33.e1-33.e9.	1.6	8
171	Consistent Biopsy Quality and Gleason Grading Within the Global Active Surveillance Global Action Plan 3 Initiative: A Prerequisite for Future Studies. <i>European Urology Oncology</i> , 2019, 2, 333-336.	5.4	8
172	Serial Molecular Profiling of Low-grade Prostate Cancer to Assess Tumor Upgrading: A Longitudinal Cohort Study. <i>European Urology</i> , 2021, 79, 456-465.	1.9	8
173	Development of a Whole-urine, Multiplexed, Next-generation RNA-sequencing Assay for Early Detection of Aggressive Prostate Cancer. <i>European Urology Oncology</i> , 2022, 5, 430-439.	5.4	8
174	Urinary MyProstateScore (MPS) to Rule out Clinically-Significant Cancer in Men with Equivocal (PI-RADS 3) Multiparametric MRI: Addressing an Unmet Clinical Need. <i>Urology</i> , 2022, 164, 184-190.	1.0	8
175	Leveraging artificial intelligence to predict ERG gene fusion status in prostate cancer. <i>BMC Cancer</i> , 2022, 22, 494.	2.6	8
176	Inferior Vena Cava Filter Strut Perforation Discovered During Right Robotic-assisted Laparoscopic Partial Nephrectomy. <i>Urology</i> , 2012, 79, e49-e50.	1.0	7
177	Oncological Outcomes of Patients with Concomitant Bladder and Urethral Carcinoma. <i>Urologia Internationalis</i> , 2016, 97, 134-141.	1.3	7
178	Prostate Cancer Screening and the Goldilocks Principle: How Much Is Just Right?. <i>Journal of Clinical Oncology</i> , 2018, 36, 937-941.	1.6	7
179	Clinicopathological characterisation of renal cell carcinoma in young adults: a contemporary update and review of literature. <i>Histopathology</i> , 2020, 76, 875-887.	2.9	7
180	Impact of Biochemical Failure After Salvage Radiation Therapy on Prostate Cancer-specific Mortality: Competition Between Age and Time to Biochemical Failure. <i>European Urology Oncology</i> , 2018, 1, 276-282.	5.4	6

#	ARTICLE	IF	CITATIONS
181	Should all prostate needle biopsy Gleason score 4+4=8 prostate cancers be high risk? Implications for shared decision-making and patient counselling. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 78.e1-78.e6.	1.6	6
182	Comparison of biopsy under-sampling and annual progression using hidden markov models to learn from prostate cancer active surveillance studies. <i>Cancer Medicine</i> , 2020, 9, 9611-9619.	2.8	6
183	Multigene Profiling of Circulating Tumor Cells (CTCs) for Prognostic Assessment in Treatment-Naïve Metastatic Hormone-Sensitive Prostate Cancer (mHSPC). <i>International Journal of Molecular Sciences</i> , 2022, 23, 4.	4.1	6
184	Comparison of prostate cancer diagnosis in patients receiving unrelated urological and non-urological cancer care. <i>BJU International</i> , 2013, 112, 161-168.	2.5	5
185	Restaging Transurethral Resection for Non-Muscle Invasive Bladder Cancer. <i>Urologic Clinics of North America</i> , 2013, 40, 295-304.	1.8	5
186	Pelvic lymph node dissection at robot-assisted radical prostatectomy: Assessing utilization and nodal metastases within a statewide quality improvement consortium. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 198-203.	1.6	5
187	Initial Findings from a High Genetic Risk Prostate Cancer Clinic. <i>Urology</i> , 2021, 156, 96-103.	1.0	5
188	Molecular Characterization of Clear Cell Renal Cell Carcinoma Reveals Prognostic Significance of Epithelial-mesenchymal Transition Gene Expression Signature. <i>European Urology Oncology</i> , 2022, 5, 92-99.	5.4	5
189	Active Surveillance for Men Younger than 60 Years or with Intermediate-risk Localized Prostate Cancer. Descriptive Analyses of Clinical Practice in the Movember GAP3 Initiative. <i>European Urology Open Science</i> , 2022, 41, 126-133.	0.4	5
190	Screening for Prostate Cancer—Beyond Total PSA, Utilization of Novel Biomarkers. <i>Current Urology Reports</i> , 2015, 16, 63.	2.2	4
191	Rare Presentation of Metastatic Cystic Trophoblastic Tumor in a Patient Without Prior Chemotherapy. <i>Urology Case Reports</i> , 2017, 13, 154-157.	0.3	4
192	Association of age with response to preoperative chemotherapy in patients with muscle-invasive bladder cancer. <i>World Journal of Urology</i> , 2021, 39, 4345-4354.	2.2	4
193	Prostate Cancer With Peritoneal Carcinomatosis: A Robotic-assisted Radical Prostatectomy-based Case Series. <i>Urology</i> , 2022, 167, 171-178.	1.0	4
194	Tissue-based genomics. <i>Current Opinion in Urology</i> , 2019, 29, 598-604.	1.8	3
195	Optimizing Prostate Cancer Surveillance: Using Data-driven Models for Informed Decision-making. <i>European Urology</i> , 2019, 75, 918-919.	1.9	3
196	Impact of the MyProstateScore (MPS) Test on the Clinical Decision to Undergo Prostate Biopsy: Results From a Contemporary Academic Practice. <i>Urology</i> , 2020, 145, 204-210.	1.0	3
197	Rethinking the one-size-fits-most approach to venous thromboembolism prophylaxis after radical cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 797.e1-797.e6.	1.6	3
198	Delayed Urological Cancer Care during the COVID-19 Pandemic: Urologists'™ Experience. <i>Urology Practice</i> , 2021, 8, 367-372.	0.5	3

#	ARTICLE	IF	CITATIONS
199	Treatment in the absence of disease reclassification among men on active surveillance for prostate cancer. <i>Cancer</i> , 2022, 128, 269-274.	4.1	3
200	Prostate cancer clinical trial completion: The role of geography. <i>Contemporary Clinical Trials</i> , 2021, 111, 106600.	1.8	3
201	Active Surveillance: Very Much "Preferred" for Low-Risk Prostate Cancer. <i>Journal of Urology</i> , 2022, 207, 262-264.	0.4	3
202	Evaluating the Outcomes of Active Surveillance in Grade Group 2 Prostate Cancer: Prospective Results from the Canary PASS Cohort. <i>Journal of Urology</i> , 2022, 207, 805-813.	0.4	3
203	Germline mutations in penetrant cancer predisposition genes are rare in men with prostate cancer selecting active surveillance. <i>Cancer Medicine</i> , 2022, , .	2.8	3
204	Ureteral Involvement Within an Incarcerated Inguinal Hernia in a Patient With Crossed-fused Renal Ectopia. <i>Urology Case Reports</i> , 2016, 7, 20-22.	0.3	2
205	Development and Validation of a Genomic Tool to Predict Seminal Vesicle Invasion in Adenocarcinoma of the Prostate. <i>JCO Precision Oncology</i> , 2020, 4, 1228-1238.	3.0	2
206	Association of Urinary MyProstateScore, Age, and Prostate Volume in a Longitudinal Cohort of Healthy Men: Long-term Findings from the Olmsted County Study. <i>European Urology Open Science</i> , 2021, 29, 30-35.	0.4	2
207	Association of MyProstateScore (MPS) with prostate cancer grade in the radical prostatectomy specimen. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 4.e1-4.e7.	1.6	2
208	Editorial Comment. <i>Journal of Urology</i> , 2013, 189, 460-461.	0.4	1
209	Diagnostic accuracy of the PROMIS study. <i>Lancet, The</i> , 2017, 390, 362.	13.7	1
210	Pathologically Node-Positive Prostate Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2020, 26, 58-63.	2.0	1
211	Understanding the Barriers to Neoadjuvant Chemotherapy in Patients with Muscle Invasive Bladder Cancer: A Quality Improvement Initiative. <i>Urology Practice</i> , 2021, 8, 217-225.	0.5	1
212	Genetically Informed Prostate Cancer Screening. <i>Urologic Clinics of North America</i> , 2021, 48, 373-386.	1.8	1
213	Effect of Diagnostic Biopsy Practice Location on Grade/Volume Reclassification in Active Surveillance for Prostate Cancer: A Multicenter Analysis from the Canary PASS Cohort. <i>Urology Practice</i> , 2021, 8, 576-582.	0.5	1
214	PD62-09 "EVALUATING THE OUTCOMES OF ACTIVE SURVEILLANCE IN GLEASON GRADE GROUP 2 PROSTATE CANCER. <i>Journal of Urology</i> , 2020, 203, e1289.	0.4	1
215	Impact of Prostate Health Index Results for Prediction of Biopsy Grade Reclassification During Active Surveillance. <i>Journal of Urology</i> , 0, , .	0.4	1
216	Editorial Comment. <i>Journal of Urology</i> , 2012, 188, 2127-2128.	0.4	0

#	ARTICLE	IF	CITATIONS
217	Editorial Comment. Urology, 2014, 84, 1432-1433.	1.0	0
218	Reply. Urology, 2014, 84, 379.	1.0	0
219	Author Reply. Urology, 2017, 102, 99.	1.0	0
220	Tradeoffs in Refining the Diagnosis of Prostate Cancer. European Urology, 2018, 74, 729-730.	1.9	0
221	Comprehensive molecular profiling of multifocal prostate cancer challenges the robustness of prostate cancer prognostic signatures. European Urology Supplements, 2018, 17, e539.	0.1	0
222	EDITORIAL COMMENT. Urology, 2019, 126, 82.	1.0	0
223	Evaluating the Evidence to Support Clinical Use of the 22-Gene Genomic Classifier (Decipher) in Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2020, 108, e902-e903.	0.8	0
224	PCN166 Comparative Effectiveness and Cost-Effectiveness of Reflex Testing Men with Intermediate PSA Levels: A Systematic Model-Based Analysis. Value in Health, 2021, 24, S50.	0.3	0
225	Reply by Authors. Journal of Urology, 2021, 206, 1156.	0.4	0
226	Targeting Efferocytic M2 Monocytes and Macrophages Offers Therapeutic Promise in Prostate Cancer Skeletal Metastasis. FASEB Journal, 2015, 29, LB457.	0.5	0
227	Adjuvant Radiation Therapy for High-Risk Post-prostatectomy Patients. , 2018, , 81-99.		0
228	Better Understanding the Timing of Androgen Deprivation (TOAD) Trial Outcomes: Impacts of Prior ADT. JNCI Cancer Spectrum, 0, , .	2.9	0
229	Radical prostatectomy for patients with high-risk, very-high risk, or radiographic suspicion for metastatic prostate cancer: Perioperative and early oncologic results from the MUSIC statewide collaborative. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 380.e1-380.e9.	1.6	0